Marcus McKenzie, MD
Cardiovascular Disease · Plano, TXNPI 1588640213
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 323 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Novartis at 24.8% of the total. 2025 is the largest year on record at $1,406, 2.1 times the $662 reported in 2019.
Across 323 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Novo Nordisk$608
- Astellas Pharma US Inc$530
- Merck$320
- Amarin Pharma, Inc.$283
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$278
- plus $3K from 28 others
Across 105 payments — averaging $660.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$48K
- Boehringer Ingelheim Pharma GmbH & Co.kg$17K
- Kowa Research Institute, Inc.$3K
- Amarin Pharma, Inc.$1K
- Eisai Inc.$240
What the payments were for
- Food & beverage$6,02199%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 81 | $1,504 |
| Novo Nordisk | 33 | $608 |
| Astellas Pharma US Inc | 30 | $530 |
| Merck | 17 | $320 |
| Amarin Pharma, Inc. | 16 | $283 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $278 |
| Amgen | 27 | $259 |
| Johnson & Johnson(2 entities) | 18 | $240 |
| Alnylam Pharmaceuticals Inc. | 4 | $208 |
| Regeneron Healthcare Solutions, Inc. | 12 | $204 |
| Kiniksa Pharmaceuticals International, PLC | 7 | $196 |
| Heartflow, Inc. | 2 | $179 |
| E.r. Squibb & Sons, L.L.C. | 9 | $178 |
| Inspire Medical Systems, Inc. | 4 | $120 |
| Abbott | 1 | $119 |
| Pfizer | 8 | $117 |
| Itamar Medical Inc | 3 | $94 |
| Philips North America LLC | 2 | $81 |
| Bayer | 4 | $77 |
| Boehringer Ingelheim | 4 | $57 |
| AstraZeneca | 4 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Boston Scientific | 2 | $44 |
| Tactile Systems Technology Inc | 3 | $38 |
| Medtronic | 1 | $38 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Bridgebio Pharma, Inc. | 1 | $26 |
| Vifor Pharma, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $23 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Althera Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$143
- AMVUTTRA$141
- AMPLATZER AMULET$119
How this compares
$6,074 in reported general payments places this provider in the 65th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 382 | $477,749 |
| XareltoRivaroxaban | 122 | $157,873 |
| Repatha SureclickEvolocumab | 64 | $76,853 |
| EntrestoSacubitril/Valsartan | 39 | $58,601 |
| Praluent PenAlirocumab | 63 | $51,170 |
| JardianceEmpagliflozin | 24 | $36,461 |
| FarxigaDapagliflozin Propanediol | 14 | $20,216 |
| BrilintaTicagrelor | 16 | $18,781 |
| Metoprolol Succinate | 520 | $7,925 |
| Ranolazine ErRanolazine | 70 | $7,287 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $6,255 |
| Rosuvastatin Calcium | 406 | $5,438 |
| Atorvastatin Calcium | 543 | $5,303 |
| Olmesartan Medoxomil | 150 | $2,989 |
| Amlodipine Besylate | 443 | $2,986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $117 | $477,749382 claims |
| Johnson & JohnsonXarelto | $240 | $157,873122 claims |
| NovartisEntresto | $1,504 | $58,60139 claims |
| AstraZenecaFarxiga, Brilinta | $55 | $38,99730 claims |
| Boehringer IngelheimJardiance | $57 | $36,46124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Plano
- Sahil BakshiPlano$167K
- David RawitscherPlano$122K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.